Can a smartphone app keep heart patients out of the hospital? new study aims to find out.
NCT ID NCT07557147
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study looks at whether a digital tool called Luscii is practical and acceptable for people with a rare heart condition called ATTR-CM. About 60 adults in Austria, Germany, and Italy will use a smartphone app and home devices to share health information with their care team. The goal is to see if remote monitoring can help catch problems early and improve communication between clinic visits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medizinische Universität Innsbruck
Innsbruck, 6020, Austria
-
Policlinico San Matteo di Pavia
Pavia, 27100, Italy
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug duo aims to stop rare heart disease in its tracks
- Experimental drug shows promise for stiff heart disease
- New heart drug acoramidis tested in Real-World setting
- New drug aims to cut heart deaths in rare heart condition
- New hope for rare heart disease: experimental drug tested for long-term safety